Can Pharmaceutical Care Interventions Improve Type 2 Diabetes Management?

Published Oct 8, 2013
Enugu State, Nigeria - Cost-utility analysis was developed to help decision makers compare the values of alternative interventions. With the increasing demand for better management of type 2 diabetes, attention has been focused on the potential benefits of pharmaceutical care (PC) to improve patients’ health outcomes. In the study, ‘‘Cost-Utility Analysis of Pharmaceutical Care Intervention Versus Usual Care in Management of Nigerian Type 2 Diabetes Patients,’’ published in Value in Health Regional Issue, researchers found that the pharmaceutical care intervention was very cost-effective. The PC intervention led to incremental cost and effect of NGN 10,623 ($69) and 0.12 QALY gained respectively with an associated ICUR of NGN 88,525 ($571)/QALY gained. The extra cost paid for extra QALY is rational as it saves future expenditures and improves the quality of life of the patients. Lead author, Maxwell Adibe, PhD from the University of Nigeria, states, “The results are of interest to health economists and health service researchers, in particular.  These results should be considered by decision makers when allocating resources to diabetes care.” The full study, “Cost-Utility Analysis of Pharmaceutical Care Intervention Versus Usual Care in Management of Nigerian Type 2 Diabetes Patients,” is published in Value in Health Regional Issues.
Value in Health Regional Issues  (ISSN 2212-1099) is a scientific journal that encourages and enhances the science of pharmacoeconomic/health economic and health outcomes research and its use in health care decisions. The journal is published up to three times a year with one issue focusing on the Asia region, one issue focusing on the Latin America region, and one issue focusing on the Central & Eastern Europe, Western Asia and Africa regions. The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

Related Stories

Value in Health Regional Issues Expands Editorial Scope and Reveals Plans to Transition to Gold Open Access Model

Jan 23, 2024

Value in Health Regional Issues, an official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced the expansion of its editorial scope and its plan to transition to a gold open access journal.

Empowering Change: Transforming Health Systems in Low- and Middle-Income Countries

Jan 22, 2024

ISPOR announced the publication of a special themed section of research papers in Value in Health Regional Issues that highlight innovative approaches to improving health outcomes in low- and middle-income countries through partnerships between health economics researchers and policy makers.

ISPOR’s Value in Health Regional Issues Receives Its First Impact Factor Score

Aug 7, 2023

Value in Health Regional Issues, the regionally focused journal of ISPOR, received its first-ever impact factor score this year. Value in Health, one of the top-ranked journals in the HEOR field, maintained its high ranking on the prestigious list of scholarly journals.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×